|
1
|
Alberts SR, Cervantes A and van de Velde
CJ: Gastric cancer: epidemiology, pathology and treatment. Ann
Oncol. 14(Suppl 2): ii31–ii36. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hundahl SA, Menck HR, Mansour EG and
Winchester DP: The National Cancer Data Base report on gastric
carcinoma. Cancer. 80:2333–2341. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ajani JA: Evolving chemotherapy for
advanced gastric cancer. Oncologist. 10(Suppl 3): S49–S58. 2005.
View Article : Google Scholar
|
|
4
|
Aggarwal BB and Shishodia S: Molecular
targets of dietary agents for prevention and therapy of cancer.
Biochem Pharmacol. 71:1397–1421. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Naithani R, Huma LC, Moriarty RM,
McCormick DL and Mehta G: Comprehensive review of cancer
chemopreventive agents evaluated in experimental carcinogenesis
models and clinical trials. Curr Med Chem. 15:1044–1071. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kaefer CM and Milner JA: The role of herbs
and spices in cancer prevention. J Nutr Biochem. 19:347–361. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Russo GL: Ins and outs of dietary
phytochemicals in cancer chemoprevention. Biochem Pharmacol.
74:533–544. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moiseeva EP and Manson MM: Dietary
chemopreventive phytochemicals: too little or too much? Cancer Prev
Res. 2:611–616. 2009. View Article : Google Scholar
|
|
9
|
Seifried HE, Anderson DE, Fisher EI and
Milner JA: A review of the interaction among dietary antioxidants
and reactive oxygen species. J Nutr Biochem. 18:567–579. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Luo H, Jiang BH, King SM and Chen YC:
Inhibition of cell growth and VEGF expression in ovarian cancer
cells by flavonoids. Nutr Cancer. 60:800–809. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Somerset SM and Johannot L: Dietary
flavonoid sources in Australian adults. Nutr Cancer. 60:442–449.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Chen AY, Li M, Chen C and Yao Q:
Ginkgo biloba extract kaempferol inhibits cell proliferation and
induces apoptosis in pancreatic cancer cells. J Surg Res.
148:17–23. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Choi EJ and Ahn WS: Kaempferol induced the
apoptosis via cell cycle arrest in human breast cancer MDA-MB-453
cells. Nutr Res Pract. 2:322–325. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo H, Rankin GO, Liu L, Daddysman MK,
Jiang BH and Chen YC: Kaempferol inhibits angiogenesis and VEGF
expression through both HIF dependent and independent pathways in
human ovarian cancer cells. Nutr Cancer. 61:554–563. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Luo H, Daddysman MK, Rankin GO, Jiang BH
and Chen YC: Kaempferol enhances cisplatin’s effect on ovarian
cancer cells through promoting apoptosis caused by down regulation
of cMyc. Cancer Cell Int. 10:162010. View Article : Google Scholar
|
|
16
|
Luo H, Rankin GO, Li Z, Depriest L and
Chen YC: Kaempferol induces apoptosis in ovarian cancer cells
through activating p53 in the intrinsic pathway. Food Chem.
128:513–519. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nguyen TT, Tran E, Ong CK, et al:
Kaempferol-induced growth inhibition and apoptosis in A549 lung
cancer cells is mediated by activation of MEK-MAPK. J Cell Physiol.
197:110–121. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen HJ, Lin CM, Lee CY, et al: Kaempferol
suppresses cell metastasis via inhibition of the ERK-p38-JNK and
AP-1 signaling pathways in U-2 OS human osteosarcoma cells. Oncol
Rep. 30:925–932. 2013.PubMed/NCBI
|
|
19
|
Song W, Dang Q, Xu D, et al: Kaempferol
induces cell cycle arrest and apoptosis in renal cell carcinoma
through EGFR/p38 signaling. Oncol Rep. 31:1350–1356.
2014.PubMed/NCBI
|
|
20
|
Debatin KM: Apoptosis pathways in cancer
and cancer therapy. Cancer Immunol Immunother. 53:153–159. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fisher DE: Pathways of apoptosis and the
modulation of cell death in cancer. Hematol Oncol Clin North Am.
15:931–956. ix2001. View Article : Google Scholar
|
|
22
|
Fulda S and Debatin KM: Targeting
apoptosis pathways in cancer therapy. Curr Cancer Drug Targets.
4:569–576. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Susnow N, Zeng L, Margineantu D and
Hockenbery DM: Bcl-2 family proteins as regulators of oxidative
stress. Semin Cancer Biol. 19:42–49. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Daniel PT, Schulze-Osthoff K, Belka C and
Güner D: Guardians of cell death: the Bcl-2 family proteins. Essays
Biochem. 39:73–88. 2003.PubMed/NCBI
|
|
25
|
Cory S and Adams JM: The Bcl2 family:
regulators of the cellular life-or-death switch. Nat Rev Cancer.
2:647–656. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Molinari M: Cell cycle checkpoints and
their inactivation in human cancer. Cell Prolif. 33:261–274. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cully M, You H, Levine AJ and Mak TW:
Beyond PTEN mutations: the PI3K pathway as an integrator of
multiple inputs during tumorigenesis. Nat Rev Cancer. 6:184–192.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chang F, Lee JT, Navolanic PM, et al:
Involvement of PI3K/Akt pathway in cell cycle progression,
apoptosis, and neoplastic transformation: a target for cancer
chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee KM, Lee DE, Seo SK, et al:
Phosphatidylinositol 3-kinase, a novel target molecule for the
inhibitory effects of kaempferol on neoplastic cell transformation.
Carcinogenesis. 31:1338–1343. 2010. View Article : Google Scholar : PubMed/NCBI
|
